This site is intended for US Healthcare Professionals.
This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. Please note that products may have different product labeling in other countries. The information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. This resource may include information that has not been approved by the US Food and Drug Administration. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling.
This site is intended for US Patients or Caregivers
This information does not take the place of talking with your doctor. Review the package insert for important safety information. GSK is committed to monitoring the safety of our products and we encourage you or your health care provider to report any side effect or suspected overdose to GSK at 888-825-5249.
The product information provided by this site is intended only for health care professionals, patients, consumers and caregivers in the United States. The products discussed may have different product labeling in different countries.
May 19-22, 2022 | Paris | Virtual
April 6-10, 2022 | Boston, MA
November 4-7, 2021 | Virtual
GSK identifies and funds innovative, high-quality, independent third-party educational initiatives that are designed to close healthcare professional (HCP) educational, quality, and performance gaps to improve patient health and quality of life. GSK provides financial support for independent medical education (IME) for HCPs, including certified continuing medical education (CME, CE), with a grant.
Educational providers are fully compliant with the ACCME (and other nationally recognized accrediting body) standards for commercial support and design and deliver all activities (including content, faculty, speakers, and educational materials) independent from GSK control, influence, and involvement.
These initiatives offer opportunities for continual learning regarding educational topics and are free for learners to access. For more information about any of these initiatives, please click the link to be directed to the educational provider's website. All questions about these activities should be directed to the educational provider listed for each activity, not to GSK, as these are not GSK initiatives.
Educational initiatives to be posted soon
Southwest Nephrology | Mar 17-18, 2022 | Scottsdale, AZ
RPA | Mar 24-27, 2022 | Dallas, TX
AMCP | Mar 29-Apr 1, 2022 | Chicago, IL
NKF | Apr 6-10, 2022 | Boston, MA
ANNA | May 22-25, 2022 | Fort Worth, TX
Heart in Diabetes | Jun 24-26, 2022 | Philadelphia, PA (Hybrid)
ASN | Nov 1-6, 2022 | Orlando, FL
Anemia of Chronic Kidney Disease | Phase II | Phase III | Phase IV |
---|---|---|---|
|
|||
ASCEND-D: Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Dialysis |
NCT02879305 | ||
ASCEND-ND: Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Non-dialysis |
NCT02876835 | ||
ASCEND-TD: Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Three-times Weekly Dosing of Dialysis |
NCT03400033 | ||
ASCEND-ID: Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Incident Dialysis |
NCT03029208 | ||
ASCEND-NHQ: Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat-Non-dialysis, Hemoglobin & Quality of Fife |
NCT03409107 |
To report suspected adverse reactions, please call us at 1-888-825-5249, or call the FDA at 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at www.fda.gov/medwatch.
You are encouraged to report vaccine adverse reactions to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967.
First Lastname
Title
First Lastname
Title
First Lastname
Title
First Lastname
Title
First Lastname
Title
First Lastname
Title
December 1-4, 2018
March 16-19, 2019
For a copy of a poster please call 1-877-475-6448
June 11-21, 2020 | Virtual
Dec 10–14, 2019 | San Antonio, Texas
Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer
September 9-12, 2020 | Virtual
September 9-12, 2020 | Virtual
1. Symposium: The Evolving Therapeutic Landscape in Relapsed/Refractory Multiple Myeloma
April 10-15, 2021 and May 17-21, 2021 | Virtual
4. POSTER: Meta-analysis of pazopanib and trabectedin in 2L+ metastatic synovial sarcoma (2L+ mSS)
5. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries
March 19-25, 2021 | Virtual
April 29-May 3, 2020 | Virtual
October 23-25, 2021 | Prague, Czech Republic
3. POSTER: The correlation between PFS and OS in Patient with Ovarian Cancer after Debulking Surgery
April 8-13, 2022 | New Orleans, LA
3. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network
March 18-21, 2022 | Phoenix, AZ
March 18-21, 2022 | Phoenix, AZ
December 11-14, 2021 | Atlanta, GA
8. PUBLICATION ONLY: Real-World Assessment of Prior Treatment Patterns in Patients Receiving Belantamab Mafodotin Using A Longitudinal Pharmacy and Medical Open Source Claims Database
9. PUBLICATION ONLY: A Retrospective Database Analysis of Treatment Pathways in US Medicare Patients with Multiple Myeloma Following Sequential Treatment with Lenalidomide and a Proteasome Inhibitor
October 23-25, 2021 | Prague, Czech Republic
Apr 27, 2020 | Virtual Annual Meeting I
Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19)
Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pathogenesis, Diagnosis, and Management
The Role of Eosinophilic and Their Potential Heterogeneity in Airways Disease
April 20, 22, 27, 29, 2021 | Virtual
1. SYMPOSIUM: Managing immune-related adverse events with checkpoint inhibitors
January 15-17, 2021 | Virtual
21. PUBLICATION ONLY: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out?
22. PUBLICATION ONLY: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting
23. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab
24. PUBLICATION ONLY: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM)
25. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma
26. PUBLICATION ONLY: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review
27. PUBLICATION ONLY: Qualitative Patient Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma (mSS)
28. PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States
Belantamab mafodotin:
Dostarlimab
ICOS Agonist IgG4 Antibody
TIM-3 Antagonist Antibody (Cobolimab)
LAG-3 Antagonist Antibody (TSR-033)
STING Agonist (GSK3745417)
Bintrafusp Alfa Bifunctional TGF-β “Trap”/Anti-PD-L1 Fusion Protein
OX40 Agonist Antibody (GSK3174998)
Belantamab Mafodotin - Anti-BCMA Immunoconjugate
NY-ESO-ImmTAC (IMCnyeso)
Anti-CD96 Antibody (GSK6097608)
Molibresib BET Inhibitor
PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715)
PI3Kβ Inhibitor (GSK2636771)
Niraparib (PARP Inhibitor)
October, 2018
November 10-14, 2021 | Washington, DC
September 24-25, 2021 | Boston, MA
September 7-10, 2021 | Houston, Texas
3. PUBLICATION ONLY: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Baseline Characteristics. Abstract # MM392
September 16-21, 2021 | Virtual
4. POSTER: Impact of Residual Disease on Outcomes in Patients with Ovarian Cancer: A Meta-analysis
September 29 - October 3, 2021 | Virtual
1. POSTER: Early COVID-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab
April 23-26, 2022 | Lisbon, Portugal
November 4-7, 2021 | Virtual
1. Singh AK, et al. ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients
2. Singh AK, et al. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients
3. Singh AK, et al. Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial
4. Singh AK, et al. ASCEND program: efficacy and safety from ASCEND-D and –ND, and overall MACE findings
November 4-7, 2021 | Virtual
3. Singh AK, et al. ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. Poster No. PO0465
4. Coyne DW, et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. Poster No. PO0487
May 19-22, 2022 | Paris | Virtual
1. Obrador GT, et al. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial.
2. Singh AK, et al. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial.
3. Singh AK, et al. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials.
4. Lu E, et al. Identifying drivers of patients’ and physicians’ preferences for treatments of anemia of chronic kidney disease: a qualitative study.
5. Gowrisankar S, et al. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis.
April 6-10, 2022 | Boston, MA
1. Singh AK, et al. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials.
April 6-10, 2022 | Boston, MA
1. Singh AK, et al. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Poster No. 373
March 29 - April 1, 2022 | Chicago
June, 2019
June 1-4, 2022 | Hybrid | Copenhagen, Denmark
June 1-4, 2022 | Hybrid | Copenhagen, Denmark
1. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE
June 9-12, 2022 | Vienna, Austria | Virtual
6. PUBLICATION ONLY: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma: DREAMM-14
June 3-7, 2022 | Chicago, IL | Virtual
12. PUBLICATION ONLY: Treatment patterns and time to next treatment among patients with OC in a real-life setting in Finland: the OCRWE-Finland study
13. PUBLICATION ONLY: Quality Assurance in Ovarian Cancer (QS-OVAR)
14. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons
15. PUBLICATION ONLY: Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada
16. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials
June 3-7, 2022 | Chicago, IL | Virtual
June, 2019
1. Chupp G, Heaney LG, Pelaia G, et al. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study.
2. Corbridge T, Deb A, Germain G, et al. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US.
3. Corbridge T, Deb A, Packnett E, et al. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma.
4. Domingo Ribas C, Pavord I, Price R, et al. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study.
5. Lee JK, Schleich F, Canonica GW, et al. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study.
6. Lu E, Mu G, Alfonso-Cristancho R. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma.
1. Hwee J, Smith S, Small M, et al. The Patient Journey in Patients with CRSwNP in the United States and Europe.
2. Liu M, Bagnasco D, Matucci A, et al. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study.
3. Smith SG, Price R, Mollo MR, et al. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS.
1. Bogart M, Bancroft T, Rothnie K, et al. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study.
2. Bogart M, Han X, Bengtson L, et al. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study.
3. Rothnie KJ, Bancroft T, Bogart M, et al. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States.
4. Rothnie K, Han X, Bancroft T, et al. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study.
5. Zhang S, Czira A, Harley J, et al. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US.
1. Bogart M, Bunner S, Johnson MG, et al. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD).
2. Bogart M, Bengtson L, Rothnie K, et al. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study.
3. Bogart M, Han X, Bengtson L, et al. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study.
4. Bogart M, Germain G, Laliberté F, et al. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S.
5. Ismaila A, Haeussler K, Czira A, et al. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations.
6. Ismaila A, Haeussler K, Czira A, et al. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis.
7. Rothnie KJ, Bancroft T, Bogart M, et al. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States.
8. Rothnie K, Han X, Bengtson L, et al. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study.
9. Whittaker HR, Rothnie K, Quint JK. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England.
1. Cho E-Y, Cho J-E, Jang S-H, et al. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea.
2. Van der Palen J, Slade D, Verma M, et al. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma.
1. Cho E-Y, Cho J-E, Lee E-B, et al. An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease.
2. Ismaila A, Czira A, Haeussler K, et al. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis.
1. Cho E-Y, Lee E-B, Yang S-H, et al. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity® Ellipta™) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea.
1. Gibbons D, Marijam A, Symons JM, et al. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 – A Population Study.
2. Gibbons D, Marijam A, Morel Symons J, et al. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States – A Population Study.
1. Chaudhuri R, Canonica GW, Bals R, et al. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. [Poster No. 714; Abstract A4267].
2. Hahn B, Bogart M, Silver J, et al. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. [Poster No. 804; Abstract A7741].
3. Molfino NA, Averell CM, Hahn BA, et al. Patients with Uncontrolled Asthma Eligible for a Biologic. [Poster No. 801; Abstract A7738].
4. Moore WC, Kornmann O, Humbert M, et al. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. [Oral presentation available here; Abstract A4211].
5. Moraes F, Abreu G, Nogueira T, et al. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. [Poster No. 712; Abstract A1827].
6. Moraes F, Abreu G, Nogueira T, et al. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. [Poster No. 710; Abstract A1825].
7. Verhamme K, de Ridder M, Webb D, et al. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. [Poster No. P792; Abstract A5630].
8. Wu AC, McMahon PM, Mendelsohn A, et al. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. P742; Abstract A4771].
1. Prazma C, Bernstein D, Brightling C, et al. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. [Poster No. 1301; Abstract A1312].
1. Bell CF, Blauer-Peterson C. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. [Poster No. P1286; Abstract A6579].
1. Steinfeld J, Roufosse F, Kahn JE, et al. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. [Oral presentation available here; Abstract A4212].
1. Averell CM, Hahn BA, Zografos L, et al. Assessment of Asthma Control in Respiratory Specialist Offices in the US. [Poster No. P711; Abstract A1826].
2. Bogart M, Chastek B, White J, et al. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. [Poster No. P805; Abstract A7742].
3. Davitte J, DeBarmore B, Hinds D, et al. Asthma control among the treated U.S. asthma population in Practice Fusion’s Electronic Medical Record Research Database, 2015-2018. [Poster No. P699; Abstract A1814].
4. Fowler A, Kerstjens HAM, Bailes Z, et al. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. [Poster No. P788; Abstract A5626].
5. Kerstjens HA, Pavord ID, Peachey G, et al. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. [Oral presentation available here; Abstract A4209].
6. Lee LA, Boulet LP, Fowler A, et al. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. [Poster No. P787; Abstract A5625].
7. Molfino NA, Averell CM, Hahn BA, et al. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. [Poster No. P372; Abstract A6482]
8. Pavord ID, Fowler A, Kerstjens HA, et al. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. [Oral presentation available here; Abstract A6247].
9. Sansbury LB, Hinds D, Chao J, et al. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. [Poster No. P713; Abstract A1828]
10. Tabberer M, von Maltzahn R, Bacci E, et al. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS®: Asthma in Two Clinical Trials of Moderate to Severe Asthma. [Poster No. P786; Abstract A5624]
1. Anderson M, Drummond MB, Jain R, et al. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. [Poster No. P813; Abstract A4302].
2. Ferguson GT, Brown N, Compton C, et al. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). [Poster No. P806; Abstract A4295].
3. Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. [Poster No. P824; Abstract A4313].
4. Mularski R, Wu B, Fuoco MJ, et al. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. [Poster No. P276; Abstract A4811].
5. Mularski RA, Drummond MB, Jain R, et al. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. [Poster No. P1045; Abstract A5050].
6. Obeid D, Bansal S, Brown N, et al. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. [Poster No. 805; Abstract A4294].
7. Bjermer L, Maltais F, Vogelmeier CF, et al. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. [Poster No. P1091; Abstract A3326].
8. Cole AL, Moretz C, Mu G, et al. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. [Poster No. 817; Abstract A4306].
9. Kerwin EM, Maltais F, Boucot IH, et al. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. [Poster No. 518; Abstract A4579].
10. Kerwin EM, Bjermer L, Maltais F, et al. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1089; Abstract A3324].
11. Moretz C, Hahn B, White J, et al. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. [Poster No. 811; Abstract A4300].
12. Vogelmeier CF, Kerwin EM, Naya IP, et al. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1053; Abstract A5058].
13. Vogelmeier CF, Boucot IH, Kerwin EM, et al. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1090; Abstract A3325].
14. Keir HR, Richardson H, Mayhew D, et al. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. [Poster No. P474; Abstract A3997].
1. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility
4. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma
5. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients?
8. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count
1. Silver J, Bogart M, Molfino N, et al. Reasons why patients with severe asthma discontinue biologic treatment. Poster No. P0018.
2. Silver J, Bogart M, Molfino N, et al. Impact of mepolizumab in patients with life-threatening asthma. Poster No. P0017.
1. Nathan R, Boulet L-P, Kerstjens HA, et al. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting β2-agonist therapy. Poster No. P1483.
2. Ramesh N, Hegewald M, Maselli DJ, et al. Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys. Poster No. P1488.
3. Sule N, Fowler A, Kerstjens HA, et al. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. Oral presentation.
4. Zhang S, White J, Meeraus W, et al. Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting β2-agonist. Poster No. P1512.
1. Anzueto A, Obeid D, Bansal S, et al. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. Poster No. P1440.
2. Bogart M, Wu B, Germain G, et al. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. Poster No. P1444.
3. Calverley PMA, Celli BR, Crim C, et al. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Poster No. P1448.
4. Criner GJ, Barnes N, Brusselle G, et al. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Poster No. P1454.
5. Dransfield MT, Halpin DMG, Han MK, et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. Poster No. P1458.
6. Han MK, Bratton DJ, Hartley B, et al. Benefit–risk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. Oral presentation.
7. Hosking L, Yeo A, Hoffman J, et al. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Poster No. P1501.
8. Mannino D, Siddall J, Small M, et al. Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians. Poster No. P1446.
9. Soler X, Siddall J, Small M, et al. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). Poster No. P1445.
10. Slade D, Ray R, Moretz C, et al. Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO). Poster No. 1467.
11. Slade D, Ray R, Moretz C, et al. Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population. Poster No. 1465.
12. Slade D, Ray R, Moretz C, et al. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. Poster No. 1466.
13. McCreary G, Yawn BP, Linnell J, et al. Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. Poster No. P1481.
14. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018. Poster No. P1505.
Mar 13-16, 2020
Mar 13-16, 2020
1. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility
4. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma
5. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients?
8. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count
1. Chupp G, Lee JK, Liu MC, et al. Mepolizumab Demonstrates Real-World Clinical Effectiveness in Both Type 2 Biomarker High and Type 2 Biomarker Low Patients With Severe Asthma.[Abstract/Poster No. L81].
2. Bernstein D, Liu MC, Schleich F, et al. The Impact of Baseline Exhaled Nitric Oxide Levels and Blood Eosinophil Count on Clinical Outcomes in REALITI-A.[Abstract/Poster No. P570].
3. Lee JK, Pollard S, Liu MC, et al. Influence of Baseline Total IgE and History of Previous Omalizumab Use on the Impact of Mepolizumab in Reducing Rate of Severe Asthma Exacerbations: Results From the Real-World REALITI-A Study. [Abstract/Poster No. P574].
4. Liu MC, Schleich F, Lee JK, et al. The Clinical Benefit of Mepolizumab Treatment Is Independent of Baseline Maintenance Oral Corticosteroid Use: Results From the Real-World REALITI-A Study. [Abstract/Presentation No. P443].
1. Khoury P, Akuthota P, Baylis L, et al. Impact of Baseline Treatment, Duration of Disease, and Refractory Status on Outcomes in Mepolizumab-Treated Patients With EGPA. [Abstract/Poster No. P154].
1. Mullol J, Lund V, Wagenmann M, et al. Mepolizumab Induced Loss of Smell Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps From the SYNAPSE Study. [Abstract/Poster No. P481].
1. Germain G, Settipane RA, Abbott C, et al. Patient Characteristics and Treatment Patterns of Elderly Asthma Patients Initiating FF/UMEC/VI. [Abstract/Poster No. P275].
1. Wechsler ME, et al. Oral Corticosteroid–Sparing Effect of Mepolizumab in Patients With Eosinophilic Granulomatosis With Polyangiitis. Presented at ACAAI 2021
1. Oppenheimer J, et al. CAPTAIN study: Effects of baseline IgE levels on triple therapy response in inadequately controlled asthma. Presented at ACAAI 2021
1. Lugogo N, et al. Mepolizumab Reduces Exacerbations, OCS and Cost Among Patients with Severe Asthma and the Highest Expenditures Prior to Treatment.Presented at CHEST 2021.
2. Panettieri R, et al. Effect of once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol triple therapy on severe exacerbation rates compared with twice-daily budesonide/formoterol dual therapy in patients with chronic obstructive pulmonary disease: a post hoc analysis of the FULFIL study. Presented at CHEST 2021.
3. McCreary G, et al. The Patient’s Journey Through COPD Treatment. Presented at CHEST 2021.
4. Bogart M, et al. Burden of systemic corticosteroid utilization in COPD.Presented at CHEST 2021.
5. Bogart M, et al. Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VI.Presented at CHEST 2021.
6. Bogart M, et al. COPD Exacerbations in Patients Switched from Multiple-Inhaler Triple Therapy to FF/UMEC/VI.Presented at CHEST 2021.
1. Busse W, et al. CAPTAIN: Effects of Baseline SABA Use on Response to Triple Therapy in Patients With Inadequately Controlled Asthma on ICS/LABA.Presented at CHEST 2021.
2. Meeraus W, et al. Discontinuation and Re-initiation of Multiple Inhaler Triple Therapy in Adult Patients With Asthma: A Cohort Study. Presented at CHEST 2021.
3. Lugogo N, et al. CAPTAIN: Effects of age of asthma onset as a continuous variable on treatment outcomes.Presented at CHEST 2021.
4. Hanania NA, et al. CAPTAIN: Effects of age as a continuous variable on treatment outcomes.Presented at CHEST 2021.
5. Neffen H, et al. Is there association and correlation between patient symptom perception and asthma control? A rapid literature review.Presented at CHEST 2021.
1. Benson VS, et al. A Real-World Characterization of Nasal Polyp Patient Burden. SP467
2. Benson VS, et al. Blood and Tissue Eosinophil Counts in Recurrent Nasal Polyps Patients. SP469
1. Fokkens WJ, et al. Mepolizumab reduces the need for surgery in patients with chronic rhinosinusitis with nasal polyps.ARS-COSM 2021
1. Fiore. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing.Poster F\AAFP 2021
Oct 21-25, 2020
1. #Vaccine Twitter Influencers: Is it Just About Reach and Followers?
5. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States
6. Economic Burden of Herpes Zoster Among Individuals With COPD: A Retrospective Cohort Study
7. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination
April 30 - May 4, 2021 | Virtual
May 24 - 29, 2021 | Geneva, Switzerland
September 28 - October 2, 2021 | Virtual
September 29 - October 3, 2021 | Virtual
5. POSTER: Meta-Regression Analysis of Worldwide Herpes Zoster Incidence, Yawn et al.
October 11 - 13, 2021 | Athens, Greece
Apr 27, 2020 | Virtual Annual Meeting I
December 5-8, 2020 | Virtual
10. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA
Publication Only: Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data From the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
Publication Only: Real-world Incidence and Clinical and Economic Burden of Managing Ocular Events (OE) in Patients with Active Multiple Myeloma (MM)
September 19-21, 2020 | Virtual
September 19-21, 2020 | Virtual
November 16-19, 2020 | Virtual
NY-ESO-1 TCR T Cell (GSK3377794)
February 27-29, 2020 | Scottsdale, AZ
October 3-4, 2020 | Virtual
January 23-25, 2020 | San Francisco, CA
November 4-7, 2021 | Virtual
November 3-9, 2021 | Virtual
August 12-15, 2021 | Destin, FL | Virtual
June 2-5, 2021 | Virtual
May 29-June 2, 2020 | Virtual
May 29-June 2, 2020 | Virtual
21. PUBLICATION ONLY: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out?
22. PUBLICATION ONLY: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting
23. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab
24. PUBLICATION ONLY: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM)
25. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma
26. PUBLICATION ONLY: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review
27. PUBLICATION ONLY: Qualitative Patient Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma (mSS)
28. PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States